Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.
Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.
Company Details
- Employees
- 38
- Founded
- -
- Address
- 浙江省杭州市萧山区杭州湾信息港d栋12楼, 杭州市,浙江省 311200,china
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.ascletis.com/
- HQ
- 杭州市, 浙江省
Ascletis Pharma Inc. Questions
Ascletis Pharma Inc.'s website is https://www.ascletis.com/
Ascletis Pharma Inc.'s LinkedIn profile is https://cn.linkedin.com/company/%E6%AD%8C%E7%A4%BC%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80-%E6%9D%AD%E5%B7%9E-%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8
Ascletis Pharma Inc. has
38 employees.
View email and phone details for 38
employees at Ascletis Pharma Inc..
Ascletis Pharma Inc.'s industry is
Pharmaceutical Manufacturing
Ascletis Pharma Inc.'s top competitors are
Zealand Pharma,
Skye Bioscience Inc.,
Arrivent Biopharma,
Sgx Group,
Aardvark Therapeutics,
Cstone Pharmaceuticals,
Fractyl Health,
Antag Therapeutics,
Zyversa Therapeutics Inc.,
Corbus Pharmaceuticals.
Ascletis Pharma Inc.'s categories are Pharmaceutical Manufacturing
Ascletis Pharma Inc.'s founding year is 2013
